Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 30;106(2):483–494. doi: 10.3324/haematol.2019.230227

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2021 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 6. — Combined treatment with tyrosine kinase inhibitor plus PAI-1 inhibitor eradicates chronic myeloid leukemia - leukemic stem cells. (A) Schema for experiments. (B) Analysis of spleens taken from mice treated with saline, imatinib (IM) alone, or IM plus TM5614 in combination either with anti-MT1-MMP antibody or isotype-matched control immunoglobulin (n=6-7). (C) Representative flow cytometric profiles and percentage of chronic myeloid leukemia - leukemic stem cells (CMLLSC) in the bone marrow (BM) (n=9). (D) Kaplan Meier survival curves of serially transplanted mice (n=10-14). Data represent means ± standard devaition. Statistical significance was determined by Mann-Whitney unpaired t-test (B) or a log-rank non-parametric test (D). P<0.001, by a Kruskal-Wallis test. PAI-1: plasminogen activator inhibitor-1; GFP: green fluorescent protein.